LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway

被引:45
作者
Liu, Peng [1 ]
Xu, Bei [1 ]
Li, Jianyong [1 ]
Lu, Hua [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
LY294002; Egr-1; Leukemia; Invasion; PI3K;
D O I
10.1016/j.bbrc.2008.09.094
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
LY294002 (LY29) is a commonly used pharmacologic inhibitor of the phosphatidylinositol 3-kinase (PI3 K) and has shown antitumorigenic effect both in vivo and in vitro. Both LY29 and its inactive analogue, LY303511 (LY30), significantly up-regulated early growth response gene 1 (Egr-1) expression in HL-60 leukemic cells. However, wortmannin, another commonly used PI3K inhibitor, was not able to induce Egr-1 at the dose that completely blocked Akt phosphorylation. LY29 markedly decreased the invasive cells number through Matrigel and human umbilical vein endothelial cells (HUVECs) compared with the controls. Moreover, the inhibitory effects could be significantly abolished by Egr-1 gene silencing with siRNA technology. Our results indicated for the first time that LY29 could suppress leukemia cell invasion and migration at least in part through up-regulation of Egr-1, independent of its PI3K-Akt activity. These data provide a novel explanation for the anticancer properties of LY29 in leukemias. (C) 2008 Elsevier Inc. All rights reserved
引用
收藏
页码:187 / 190
页数:4
相关论文
共 23 条
[1]
Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein [J].
Baek, SJ ;
Kim, JS ;
Moore, SM ;
Lee, SH ;
Martinez, J ;
Eling, TE .
MOLECULAR PHARMACOLOGY, 2005, 67 (02) :356-364
[2]
Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2
[3]
LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism [J].
Choi, EK ;
Park, HJ ;
Ma, JS ;
Lee, HC ;
Kang, HC ;
Kim, BG ;
Kang, IC .
FEBS LETTERS, 2004, 559 (1-3) :141-144
[4]
Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia [J].
Gibbs, Jd ;
Liebermann, Da ;
Hoffman, B. .
ONCOGENE, 2008, 27 (01) :98-106
[5]
GIBBS JD, 2008, LEUKEMIA
[6]
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1 [J].
Kelly, BD ;
Hackett, SF ;
Hirota, K ;
Oshima, Y ;
Cai, ZQ ;
Berg-Dixon, S ;
Rowan, A ;
Yan, ZJ ;
Campochiaro, PA ;
Semenza, GL .
CIRCULATION RESEARCH, 2003, 93 (11) :1074-1081
[7]
Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of β-lapachone in human hepatocarcinoma cells [J].
Kim, Sung Ok ;
Kwon, Jae Im ;
Jeong, Yong Kee ;
Kim, Gi Young ;
Kim, Nam Deuk ;
Choi, Yung Hyun .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2007, 71 (09) :2169-2176
[8]
The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251 [J].
Liu, CT ;
Yao, J ;
Mercola, D ;
Adamson, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20315-20323
[9]
Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth [J].
Lucerna, Markus ;
Pomyje, Jiri ;
Mechtcheriakova, Diana ;
Kadl, Alexandra ;
Gruber, Florian ;
Bilban, Martin ;
Sobanov, Yuri ;
Schabbauer, Gernot ;
Breuss, Johannes ;
Wagner, Oswald ;
Bischoff, Markus ;
Clauss, Matthias ;
Binder, Bernd R. ;
Hofer, Erhard .
CANCER RESEARCH, 2006, 66 (13) :6708-6713
[10]
Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1 [J].
Moon, Y ;
Bottone, FG ;
McEntee, MF ;
Eling, TE .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (10) :1551-1558